Europe Equity Research

11 February 2010

Overweight
Reckitt Benckiser RB.L, RB/ LN
Price: 3,187p
There is growth, there is cash
Price Target: 3,700p

• Good finish to the year on Core and Pharma. Reckitt Benckiser Household Products
reported a strong set of Q409 results. Top line grew 10%, with 7% in the AC
Celine Pannuti, CFA
Core business. Margin grew 60bps though excluding a £40m restructuring (44-20) 7325-9276
charge margins were up 250bps (+40bps on the Core). Net profit of celine.pannuti@jpmorgan.com
£448m was in line (though ex the restructuring profit beat consensus by J.P. Morgan Securities Ltd.
8%). Clearly the Pharma division profit reached an all time high, but
performance in the core reassured with Europe (+1%) and Household For Specialist sales advice, please
(+3%) improving on their 0% delivery in Q309. contact
Natasha Cobden
• Encouraging outlook, margin story has leg. The outlook on the Core is (44-20) 7325 3092
for a 5% LFL and 10% profit growth (implying a 40-50bps margin natasha.z.cobden@jpmorgan.com
increase). This is in line with JPMe and a good ‘starting point’ at this
Price Performance
stage. It also comforts our view of margin upside given the European
reorganization and the renegotiation of the media contract. On sales 3,200
growth, good delivery in NA, ROW and H&PC gives us confidence on p
2,600
the 5% LFL target, even despite tough WE markets. We welcome the
2,000
focus on the core given the uncertainties on generics entrance in Pharma. Feb-09 May-09 Aug-09 Nov-09 Feb-10
While our net profit is almost unchanged our 2010 EPS is cut by 1% to
RB.L share price (p)
reflect higher share count. MSCI-Eu (rebased)

• Strong cash generation, but it stays on the BS for now. Thanks to a YTD 1m 3m 12m
strong inflow from WC, operating cash flow amounted to £1.9bn, up 46% Abs -4.9% -1.8% 5.0% 21.5%
yoy. In FY09, RB built a net cash of £220m which is expected to grow to Rel 0.4% 5.3% 7.0% -1.9%
£1bn by end 10. Management seems adamant not to resume the share
buyback though we feel an increase in dividend could be on the cards (on
top of generous 50% dividend payout). For now management is willing to
keep the cash flexibility to finance M&A opportunities though there was
no hint on the current state of affairs on the topic.
• Compelling investment. While investors ponder given the uncertainty on
M&A, we believe the equity story looks compelling given the re-assurance
of a robust growth coupled with margin upside which should lead to
double digit EPS growth on the core. At 17.6x PE 10e ex-pharma RB has
lost its premium vs sector peers (vs 20.2x L’Oreal, 16.3x Henkel, 14.7x
Unilever) and offers in our view a good entry point in the equity story.

Reckitt Benckiser (RB.L;RB/ LN)

FYE Dec 2008A 2009A 2010E 2010E 2011E 2011E Company Data
(New) (Old) (New) (Old) Price (p) 3,187
Adj. EPS FY (p) 157.81 194.73 192.28 194.93 203.98 206.39 Date Of Price 10 Feb 10
Adj P/E FY 20.2 16.4 16.6 16.3 15.6 15.4 Price Target (p) 3,700
EV/EBITDA FY 12.8 11.6 11.8 12.2 11.2 11.6 Price Target End Date 31 Dec 10
FCF Yield FY 5.3% 6.1% 6.4% 5.6% 6.5% 5.8% 52-week Range (p) 3,390 - 2,403
Revenue FY (£ mn) 6,563 7,753 7,936 7,892 8,428 8,374 Mkt Cap (£ bn) 22.84
EBITA (Calc) FY (£ mn) 1,542 1,899 1,864 1,841 1,956 1,948 Shares O/S (mn) 717
Net Attributable Income 1,120 1,418 1,408 1,403 1,502 1,486
FY (£ mn)
FCF FY (£ mn) 1,117 1,411 1,491 1,297 1,524 1,332
Source: Company data, Bloomberg, J.P. Morgan estimates.

See page 8 for analyst certification and important disclosures, including non-US analyst disclosures.
J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may
have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their
investment decision.
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Q4/FY09 Review
Table 1: Reckitt Benckiser - Quarterly sales and EBITA split, 2008-09E
In £m Q408 Q409 Q409E Comments FY08 FY09 FY09E
Sales 1,825 2,063 1,996 6,563 7,753 7,686
Europe 828 867 870 3,269 3,511 3,514
North America & Australia 567 614 619 1,766 2,160 2,165
Developing Markets 311 388 384 1,187 1,494 1,490
Pharma 119 194 123 341 588 517

Sales Growth 33.0% 13.0% 9.4% 24.6% 18.1% 17.1%

Organic 8.1% 10.1% 7.0% Strong Volume growth of +9% in Q409 9.6% 7.8% 7.0%
Organic ex pharma 5.9% 6.3% 6.0% Volume growth of 6% ex-pharma in Q409 8.1% 5.5% 5.4%
FX 18.1% 3.4% 2.9% 11.6% 10.1% 9.9%
M&A 9.5% 0.0% 0.2% 3.4% 0.2% 0.3%

Europe 19.0% 4.7% 5.1% 18.2% 7.4% 7.5%

Organic 5.4% 0.7% 1.5% Portugal, Ireland, Greece, Spain –Weak 6.6% 1.3% 1.5%
FX 16.0% 5.1% 4.7% 13.4% 6.1% 6.0%
M&A -0.8% 0.0% 0.0% -1.7% 0.0% 0.0%

North America & Australia 55.4% 8.3% 9.2% 33.3% 22.3% 22.6%
Mostly Driven by market share growth in Lysol and
Organic 2.7% 7.7% 7.1% Mucinex brands 5.6% 6.2% 6.0%
FX 23.0% 0.7% 1.4% 10.6% 15.3% 15.5%
M&A 36.8% 0.0% 0.7% 17.2% 0.9% 1.1%

Developing markets 24.8% 24.8% 23.4% 22.6% 25.9% 25.5%

Strong growth across all regions and Fabric Care,
Organic 12.3% 18.6% 16.0% Surface Care and Health & Personal Care 15.8% 16.2% 15.5%
FX 12.6% 6.1% 7.4% 6.8% 9.7% 10.0%
M&A 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Pharma 91.8% 63.0% 3.8% 61.6% 72.4% 51.8%

Organic 53.5% 65.5% 22.4% Strong growth led by Suboxone and no generics entry 45.3% 50.0% 35.0%
FX 40.4% -2.7% -14.7% 16.5% 22.4% 18.2%
M&A 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Operating Profit 525 605 588 1,535 1,891 1,874

Europe 232 204 249 782 804 849
North America & Australia 173 197 199 397 500 502
Developing Markets 54 70 70 163 216 216
Pharma 66 134 69 193 371 306

+50bps: Benefited by GM expansion +100bps,

Operating cost efficiencies. Excl. reorganization
Operating Profit margin 28.8% 29.3% 29.4% charges in Europe, margins +200bps 23.4% 24.4% 24.4%
Europe 28.0% 23.5% 28.7% +10bps excluding reorganization charges (c£40m) 23.9% 22.9% 24.2%
North America & Australia 30.5% 32.1% 32.1% +160bps: driven by Lysonl, Mucinex and Food 22.5% 23.1% 23.2%
Developing Markets 17.4% 18.0% 18.4% +60bps 13.7% 14.5% 14.5%
Pharma 55.5% 69.1% 55.7% +13.6%pt 56.6% 63.1% 59.1%
Source: Company reports and J.P. Morgan estimates.

2
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Table 2: Reckitt Benckiser - Quarterly P&L statement, 2008-09E

In £m Q408 Q409 Q409E Comments FY08 FY09 FY09E
Sales 1,825 2,063 1,996 6,563 7,753 7,686
% growth 33.0% 13.0% 9.4% 24.6% 18.1% 17.1%

Gross profit 1,119 1,285 1,233 3,890 4,664 4,612

Easing Input Costs, Strong operating leverage and
Cost Optimization Programmes (Squeeze/ x-trim)
Gross margin 61.3% 62.3% 61.8% Partly offset by negative FX on raw materials 59.3% 60.2% 60.0%

Net operating expenses -594 -680 -681 -2,385 -2,773 -2,774

as % of sales -32.5% -33.0% -34.1% -36.3% -35.8% -36.1%

incl. Media Spend -192 -207 -181 -816 -864 -838

Media spend +8% (4% LFL). Media savings re-
as % of sales -10.6% -10.1% -9.1% invested in other consumer marketing (promotions) -12.4% -11.1% -10.9%

EBIT 525 605 588 1,535 1,891 1,874

As % of sales 28.8% 29.3% 29.4% 23.4% 24.4% 24.4%

Restructuring 0 0 0 -30 0 0

Net interest -5 2 3 -31 1 2

Profit before tax 520 607 590 1,474 1,892 1,875
Tax -124 -159 -135 -354 -474 -450
Tax rate -23.8% -26.2% -22.9% FY tax rate of 25% -24.0% -25.1% -24.0%

Minorities 0 0 0 0 0 0
Net Profit 396 448 455 1,120 1,418 1,425
% growth 37.1% 14.0% 15.8% 19.4% 26.6% 27.2%
Net Profit excl. exceptionals 396 448 456 1,143 1,418 1,426
% growth 35.7% 13.9% 20.6% 26.3% 24.1% 20.6%

EPS - Diluted normalised profit (p) 54.6 60.9 63.3 Excl. European reorganization charge 64.9p 157.8 194.7 197.9
Source: Company reports and J.P. Morgan estimates.

3
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Reckitt: J.P. Morgan estimates for FY10-11

In the tables below, we present our detailed financial forecasts for 2010 and 2011.

Table 3: Reckitt Benckiser - Sales and EBITA margins, 2004-11E

2004 2005 2006 2007 2008 2009 2010E 2011E
Group Sales 3,782 4,058 4,766 5,058 6,563 7,753 7,519 7,975
Europe 1,987 2,085 2,572 2,765 3,269 3,511 3,564 3,671
North America & Australia 1,152 1,210 1,317 1,325 1,766 2,160 2,222 2,311
Developing Markets 643 763 877 968 1,187 1,494 1,733 1,993
Pharma 89 121 156 211 341 588 417 453

Sales Growth 4.3% 8.0% 17.8% 7.0% 24.6% 18.1% -3.0% 6.1%
Organic- Core sales 9.7% 4.9% 6.2% 7.8% 8.1% 5.5% 5.3% 6.1%
Organic total 10.0% 5.6% 6.9% 8.9% 9.6% 7.8% 2.8% 6.2%
FX -5.6% 2.0% -0.9% -2.6% 11.6% 10.1% -0.5% 0.0%
M&A 0.0% 0.0% 11.8% 0.9% 3.4% 0.2% 0.0% 0.0%

Europe 6.4% 4.9% 23.4% 7.5% 18.2% 7.4% 1.5% 3.0%

Organic- Core sales 8.2% 3.8% 5.9% 6.2% 6.6% 1.3% 2.0% 3.0%
FX -1.7% 1.3% -0.5% -0.1% 13.4% 6.1% -0.5% 0.0%
M&A 0.0% 0.0% 17.9% 1.2% -1.8% 0.0% 0.0% 0.0%

North America & Australia -1.6% 5.0% 8.8% 0.6% 33.3% 22.3% 2.9% 4.0%
Organic- Core sales 8.1% 3.0% 3.5% 6.8% 5.6% 6.2% 3.9% 4.0%
FX -9.5% 1.4% -1.8% -6.1% 10.6% 15.3% -1.0% 0.0%
M&A 0.0% 0.0% 7.3% 0.5% 17.2% 0.9% 0.0% 0.0%

Developing markets 5.9% 18.7% 14.9% 10.4% 22.6% 25.9% 16.0% 15.0%
Organic 16.4% 12.2% 11.1% 14.6% 15.8% 16.2% 15.0% 15.0%
FX -10.4% 5.2% -0.4% -4.7% 6.8% 9.7% 1.0% 0.0%
M&A 0.0% 0.0% 4.2% 0.5% 0.0% 0.0% 0.0% 0.0%

Pharma 30.9% 36.0% 28.9% 35.3% 61.6% 72.4% -29.0% 8.7%

Organic 30.9% 36.0% 28.9% 37.4% 45.3% 50.0% -27.3% 8.6%
FX -4.7% 1.3% -1.3% -4.1% 16.5% 22.4% -1.9% 0.0%
M&A 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Operating Profit margin 19.3% 20.1% 21.5% 22.6% 23.4% 24.4% 23.4% 23.1%
EBIT ex pharma 18.3% 18.9% 20.5% 21.2% 21.6% 21.2% 22.2% 22.7%
Europe 21.5% 22.4% 22.6% 23.4% 23.9% 22.9% 24.6% 24.8%
North America & Australia 18.4% 19.2% 22.5% 22.3% 22.5% 23.1% 23.7% 24.2%
Developing Markets 5.9% 8.9% 11.1% 13.4% 13.7% 14.5% 15.5% 17.0%
Pharma 62.9% 60.3% 53.8% 55.8% 56.6% 63.1% 44.0% 30.5%
Source: Company reports and J.P. Morgan estimates.

4
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Table 4: Reckitt - Profit & Loss Accounts, 2004-2011E

2004 2005 2006 2007 2008 2009 2010E 2011E
Net sales 3,871 4,179 4,922 5,269 6,563 7,753 7,936 8,428

Cost of sales -1,750 -1,886 -2,133 -2,197 -2,673 -3,089 -3,135 -3,287
Gross profit 2,121 2,293 2,789 3,072 3,890 4,664 4,801 5,141
Gross margin 54.8% 54.9% 56.7% 58.3% 59.3% 60.2% 60.5% 61.0%

EBITDA 749 931 1,159 1,292 1,666 2,017 1,985 2,084

EBIT 749 840 1,059 1,190 1,535 1,891 1,856 1,947
EBIT margin 19.3% 20.1% 21.5% 22.6% 23.4% 24.4% 23.4% 23.1%

Restructuring Expenses 0 0 -149 43 -30 0 0 0

Financial items 9 36 -36 -24 -31 1 21 55

Pre-tax profits 758 876 874 1,209 1,474 1,892 1,877 2,002
Tax -181 -207 -200 -271 -354 -474 -469 -501
Tax rate -23.9% -23.6% -22.9% -22.4% -24.0% -25.1% -25.0% -25.0%

Group net income 577 669 674 938 1,120 1,418 1,408 1,502
Minorities 0 0 0 0 0 0 0 0
Net Profit 577 669 674 938 1,120 1,418 1,408 1,502
Net Profit excl. exceptionals 563 653 786 905 1,143 1,418 1,408 1,502

Fully diluted EPS (p) 75.3 87.9 107.1 123.3 157.8 194.7 192.3 204.0
% growth 13.7% 16.8% 21.7% 15.2% 28.0% 23.4% -1.3% 6.1%
Source: Company reports and J.P. Morgan estimates.

5
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Table 5: Reckitt - Balance Sheet, 2004-2011E

2004 2005 2006 2007 2008 2009 2010E 2011E
Inventories 258 270 322 382 556 486 672 714
Trade and other receivables 504 545 670 682 906 928 1,096 1,163
Derivative financial instruments 11 69 1 1 1
Available for sale financial assets 570 77 19 39 6 4 4 4
Cash and cash equivalents 308 978 305 328 417 351 1,119 1,872
Total Current assets 1,640 1,870 1,316 1,442 1,954 1,770 2,892 3,754

Goodwill and other intangible assets 1,663 1,766 3,842 3,811 6,454 6,090 6,471 6,480
Property, plant and equipment 481 485 425 479 637 639 754 845
Deferred tax assets 58 77 144 106 93 121 121 121
Available for sale financial assets 25 16 16 16
Other receivables 10 15 10 30 19 25 25 25
Total Non-current assets 2,212 2,343 4,421 4,426 7,228 6,891 7,387 7,487

Total assets 3,852 4,213 5,737 5,868 9,182 8,661 10,279 11,241

Borrowings 117 88 973 487 1,571 132 132 132

Provisions for liabilities and charges 4 4 47 36 73 88 88 88
Trade and other payables 1,135 1,225 1,481 1,635 2,189 2,286 2,647 2,811
Tax liabilities 148 206 239 266 383 385 463 492
Current liabilities 1,404 1,523 2,740 2,424 4,216 2,891 3,330 3,523

Borrowings 129 80 11 5 4 4 4 4
Deferred tax liabilities 349 377 766 705 1,172 1,145 1,145 1,145
Retirement benefit obligations 253 261 216 187 316 393 393 393
Provisions for liabilities and charges 11 10 15 19 31 36 36 36
Tax liabilities 98 85 100 120 128 158 158 158
Other non-current liabilities 28 21 23 23 21 20 20 20
Total Non-current liabilities 868 834 1,131 1,059 1,672 1,756 1,756 1,756

Total liabilities 2,272 2,357 3,871 3,483 5,888 4,647 5,086 5,279
Net assets 1,580 1,856 1,866 2,385 3,294 4,014 5,193 5,962

Equity 1,577 1,855 1,863 2,383 3,292 4,012 5,191 5,960

Equity minority interests 3 1 3 2 2 2 2 2
Total Liabilities+Equity 3,852 4,213 5,737 5,868 9,182 8,661 10,279 11,241
Source: Company reports and J.P. Morgan estimates.

Table 6: Reckitt - Cash Flow Statements, 2004-2011E

2004 2005 2006 2007 2008 2009 2010E 2011E
Operating Profit 749 840 1,059 1,190 1,535 1,891 1,856 1,947
Depreciation and Amortisation 97 91 97 93 107 139 129 137
Tax -189 -157 -181 -232 -280 -371 -369 -401
Net Interests 8 34 -30 -24 -27 -4 21 55
Others 44 28 77 -43 64 59 59 59
incl. Reorganisation costs paid 0 0 -149 43 -30 0 0 0
Cash Earnings 709 836 873 1,027 1,369 1,714 1,696 1,798

Change in Working Capital 24 -13 -49 -49 -36 -145 -7 -54

Capital Expenditure -83 -78 -88 -134 -216 -158 -198 -219
Free Cash Flow 650 745 736 844 1,117 1,411 1,491 1,524
Free Cash Flow margin 16.8% 17.8% 15.0% 16.0% 17.0% 18.2% 18.8% 18.1%

Net acquisitions -1 -4 -1,893 0 -1,081 0 0 0

Asset disposals 9 17 19 279 9 11 0 0
Cash Flow after Investments 658 758 -1,138 1,123 45 1,422 1,491 1,524

Share buy-back -283 -300 -300 -300 -300 0 0 0

Dividends Paid -216 -262 -300 -358 -441 -648 -723 -771
Other 30 36 56 52 63 131 0 0
Total Change in Net Cash 189 232 -1,682 517 -633 905 768 753
Source: Company reports and J.P. Morgan estimates.

6
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Valuation Methodology and Risks

Reckitt Benckiser (Overweight; Price Target 3,700p)
Valuation Methodology
We retain our OW rating on ReckittBenckiser with a DCF-based Dec-10 target price
of £37. We use a WACC of 9%, and LT growth rate of 2%.

Risks to Our View

We believe the key risks that could keep our rating and target price from being
achieved include the following: a weakening of the dollar and the euro against
sterling, high raw material costs, and a deterioration in trading conditions in Europe
and the US, driven by weaker consumer demand as well as heightened competition.
Any update on the potential to offset the loss of the exclusivity rights expiry in the
Pharmaceuticals division could have a positive impact on valuation.

7
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Analyst Certification:
The research analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily
responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies, with
respect to each security or issuer that the research analyst covers in this research) that: (1) all of the views expressed in this report
accurately reflect his or her personal views about any and all of the subject securities or issuers; and (2) no part of any of the research
analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the
research analyst(s) in this report.
Important Disclosures

• Market Maker/ Liquidity Provider: JPMSL and/or an affiliate is a market maker and/or liquidity provider in Reckitt Benckiser.
• Client of the Firm: Reckitt Benckiser is or was in the past 12 months a client of JPMSI; during the past 12 months, JPMSI provided
to the company non-investment banking securities-related services and non-securities-related services.
• Investment Banking (next 3 months): JPMSI or its affiliates expect to receive, or intend to seek, compensation for investment
banking services in the next three months from Reckitt Benckiser.
• Non-Investment Banking Compensation: JPMSI has received compensation in the past 12 months for products or services other
than investment banking from Reckitt Benckiser. An affiliate of JPMSI has received compensation in the past 12 months for
products or services other than investment banking from Reckitt Benckiser.

Reckitt Benckiser (RB.L) Price Chart

Date Rating Share Price Price Target

5,229 OW 2,950p OW 3,150p OW 3,700p (p) (p)
4,648 26-Oct-06 OW 2300 2500
OW 2,600p OW 3,000p OW 3,400p
4,067 08-Feb-07 OW 2484 2600
OW 2,500p OW 3,000pOW 3,150p
OW 3,400p OW 3,000p OW 3,300p 26-Apr-07 OW 2628 2950
3,486
25-Jul-07 OW 2748 3000
Price(p) 2,905 10-Dec-07 OW 2924 3150
2,324 23-Jan-08 OW 2584 3000
24-Jan-08 OW 2447 3150
1,743
26-Mar-08 OW 2763 3400
1,162 10-Feb-09 OW 2705 3000
581 24-Sep-09 OW 2970 3300
28-Oct-09 OW 3016 3400
0
Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec
27-Jan-10 OW 3221 3700
06 06 07 07 07 07 08 08 08 08 09 09 09 09

Source: Bloomberg and J.P. Morgan; price data adjusted for stock splits and dividends.
This chart shows J.P. Morgan's continuing coverage of this stock; the current analyst may or may not have covered it
over the entire period.
J.P. Morgan ratings: OW = Overweight, N = Neutral, UW = Underweight.

Explanation of Equity Research Ratings and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight [Over the next six to twelve months, we expect this stock will outperform the
average total return of the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] Neutral [Over the next six to twelve
months, we expect this stock will perform in line with the average total return of the stocks in the analyst’s (or the analyst’s team’s)
coverage universe.] Underweight [Over the next six to twelve months, we expect this stock will underperform the average total return of
the stocks in the analyst’s (or the analyst’s team’s) coverage universe.] The analyst or analyst’s team’s coverage universe is the sector
and/or country shown on the cover of each publication. See below for the specific stocks in the certifying analyst(s) coverage universe.

Coverage Universe: Celine Pannuti, CFA: Beiersdorf (BEIG.DE), Givaudan (GIVN.VX), Henkel (HNKG_p.DE), L'Oréal
(OREP.PA), Oriflame (ORIsdb.ST), Reckitt Benckiser (RB.L), SCA (SCAb.ST), Unilever NV (UNIA.AS), Unilever plc
(ULVR.L)

8
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

J.P. Morgan Equity Research Ratings Distribution, as of December 31, 2009

Overweight Neutral Underweight
(buy) (hold) (sell)
JPM Global Equity Research Coverage 42% 44% 14%
IB clients* 58% 57% 42%
JPMSI Equity Research Coverage 41% 49% 10%
IB clients* 78% 73% 57%
*Percentage of investment banking clients in each rating category.
For purposes only of NASD/NYSE ratings distribution rules, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold
rating category; and our Underweight rating falls into a sell rating category.

Valuation and Risks: Please see the most recent company-specific research report for an analysis of valuation methodology and risks on
any securities recommended herein. Research is available at http://www.morganmarkets.com , or you can contact the analyst named on
the front of this note or your J.P. Morgan representative.

Analysts’ Compensation: The equity research analysts responsible for the preparation of this report receive compensation based upon
various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues, which
include revenues from, among other business units, Institutional Equities and Investment Banking.

Registration of non-US Analysts: Unless otherwise noted, the non-US analysts listed on the front of this report are employees of non-US
affiliates of JPMSI, are not registered/qualified as research analysts under NASD/NYSE rules, may not be associated persons of JPMSI,
and may not be subject to NASD Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public
appearances, and trading securities held by a research analyst account.

Other Disclosures

J.P. Morgan is the global brand name for J.P. Morgan Securities Inc. (JPMSI) and its non-US affiliates worldwide.
Options related research: If the information contained herein regards options related research, such information is available only to persons who
have received the proper option risk disclosure documents. For a copy of the Option Clearing Corporation’s Characteristics and Risks of
Standardized Options, please contact your J.P. Morgan Representative or visit the OCC’s website at
http://www.optionsclearing.com/publications/risks/riskstoc.pdf.
Legal Entities Disclosures
U.S.: JPMSI is a member of NYSE, FINRA and SIPC. J.P. Morgan Futures Inc. is a member of the NFA. JPMorgan Chase Bank, N.A. is a
member of FDIC and is authorized and regulated in the UK by the Financial Services Authority. U.K.: J.P. Morgan Securities Ltd. (JPMSL) is a
member of the London Stock Exchange and is authorised and regulated by the Financial Services Authority. Registered in England & Wales No.
2711006. Registered Office 125 London Wall, London EC2Y 5AJ. South Africa: J.P. Morgan Equities Limited is a member of the Johannesburg
Securities Exchange and is regulated by the FSB. Hong Kong: J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated
by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong. Korea: J.P. Morgan Securities (Far East) Ltd,
Seoul Branch, is regulated by the Korea Financial Supervisory Service. Australia: J.P. Morgan Australia Limited (ABN 52 002 888 011/AFS
Licence No: 238188) is regulated by ASIC and J.P. Morgan Securities Australia Limited (ABN 61 003 245 234/AFS Licence No: 238066) is a
Market Participant with the ASX and regulated by ASIC. Taiwan: J.P.Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock
Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. India: J.P. Morgan India Private Limited is a member of
the National Stock Exchange of India Limited and Bombay Stock Exchange Limited and is regulated by the Securities and Exchange Board of
India. Thailand: JPMorgan Securities (Thailand) Limited is a member of the Stock Exchange of Thailand and is regulated by the Ministry of
Finance and the Securities and Exchange Commission. Indonesia: PT J.P. Morgan Securities Indonesia is a member of the Indonesia Stock
Exchange and is regulated by the BAPEPAM LK. Philippines: J.P. Morgan Securities Philippines Inc. is a member of the Philippine Stock
Exchange and is regulated by the Securities and Exchange Commission. Brazil: Banco J.P. Morgan S.A. is regulated by the Comissao de Valores
Mobiliarios (CVM) and by the Central Bank of Brazil. Mexico: J.P. Morgan Casa de Bolsa, S.A. de C.V., J.P. Morgan Grupo Financiero is a
member of the Mexican Stock Exchange and authorized to act as a broker dealer by the National Banking and Securities Exchange Commission.
Singapore: This material is issued and distributed in Singapore by J.P. Morgan Securities Singapore Private Limited (JPMSS) [MICA (P)
020/01/2010 and Co. Reg. No.: 199405335R] which is a member of the Singapore Exchange Securities Trading Limited and is regulated by the
Monetary Authority of Singapore (MAS) and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore) which is regulated by the
MAS. Malaysia: This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X) which is a
Participating Organization of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission in
Malaysia. Pakistan: J. P. Morgan Pakistan Broking (Pvt.) Ltd is a member of the Karachi Stock Exchange and regulated by the Securities and
Exchange Commission of Pakistan. Saudi Arabia: J.P. Morgan Saudi Arabia Ltd. is authorised by the Capital Market Authority of the Kingdom
of Saudi Arabia (CMA) to carry out dealing as an agent, arranging, advising and custody, with respect to securities business under licence number
35-07079 and its registered address is at 8th Floor, Al-Faisaliyah Tower, King Fahad Road, P.O. Box 51907, Riyadh 11553, Kingdom of Saudi

9
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

Arabia. Dubai: JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered
address is Dubai International Financial Centre - Building 3, Level 7, PO Box 506551, Dubai, UAE.
Country and Region Specific Disclosures
U.K. and European Economic Area (EEA): Unless specified to the contrary, issued and approved for distribution in the U.K. and the EEA by
JPMSL. Investment research issued by JPMSL has been prepared in accordance with JPMSL's policies for managing conflicts of interest arising
as a result of publication and distribution of investment research. Many European regulators require that a firm to establish, implement and
maintain such a policy. This report has been issued in the U.K. only to persons of a kind described in Article 19 (5), 38, 47 and 49 of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document must
not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is only
available to relevant persons and will be engaged in only with relevant persons. In other EEA countries, the report has been issued to persons
regarded as professional investors (or equivalent) in their home jurisdiction. Australia: This material is issued and distributed by JPMSAL in
Australia to “wholesale clients” only. JPMSAL does not issue or distribute this material to “retail clients.” The recipient of this material must not
distribute it to any third party or outside Australia without the prior written consent of JPMSAL. For the purposes of this paragraph the terms
“wholesale client” and “retail client” have the meanings given to them in section 761G of the Corporations Act 2001. Germany: This material is
distributed in Germany by J.P. Morgan Securities Ltd., Frankfurt Branch and J.P.Morgan Chase Bank, N.A., Frankfurt Branch which are
regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht. Hong Kong: The 1% ownership disclosure as of the previous month end
satisfies the requirements under Paragraph 16.5(a) of the Hong Kong Code of Conduct for Persons Licensed by or Registered with the Securities
and Futures Commission. (For research published within the first ten days of the month, the disclosure may be based on the month end data from
two months’ prior.) J.P. Morgan Broking (Hong Kong) Limited is the liquidity provider for derivative warrants issued by J.P. Morgan Structured
Products B.V. and listed on the Stock Exchange of Hong Kong Limited. An updated list can be found on HKEx website:
http://www.hkex.com.hk/prod/dw/Lp.htm. Japan: There is a risk that a loss may occur due to a change in the price of the shares in the case of
share trading, and that a loss may occur due to the exchange rate in the case of foreign share trading. In the case of share trading, JPMorgan
Securities Japan Co., Ltd., will be receiving a brokerage fee and consumption tax (shouhizei) calculated by multiplying the executed price by the
commission rate which was individually agreed between JPMorgan Securities Japan Co., Ltd., and the customer in advance. Financial Instruments
Firms: JPMorgan Securities Japan Co., Ltd., Kanto Local Finance Bureau (kinsho) No. 82 Participating Association / Japan Securities Dealers
Association, The Financial Futures Association of Japan. Korea: This report may have been edited or contributed to from time to time by
affiliates of J.P. Morgan Securities (Far East) Ltd, Seoul Branch. Singapore: JPMSS and/or its affiliates may have a holding in any of the
securities discussed in this report; for securities where the holding is 1% or greater, the specific holding is disclosed in the Important Disclosures
section above. India: For private circulation only, not for sale. Pakistan: For private circulation only, not for sale. New Zealand: This
material is issued and distributed by JPMSAL in New Zealand only to persons whose principal business is the investment of money or who, in the
course of and for the purposes of their business, habitually invest money. JPMSAL does not issue or distribute this material to members of "the
public" as determined in accordance with section 3 of the Securities Act 1978. The recipient of this material must not distribute it to any third
party or outside New Zealand without the prior written consent of JPMSAL. Canada: The information contained herein is not, and under no
circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, or solicitation of
an offer to buy securities described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in
Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only
by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the dealer registration requirement
in the relevant province or territory of Canada in which such offer or sale is made. The information contained herein is under no circumstances to
be construed as investment advice in any province or territory of Canada and is not tailored to the needs of the recipient. To the extent that the
information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a province or territory
of Canada, any trades in such securities must be conducted through a dealer registered in Canada. No securities commission or similar regulatory
authority in Canada has reviewed or in any way passed judgment upon these materials, the information contained herein or the merits of the
securities described herein, and any representation to the contrary is an offence. Dubai: This report has been issued to persons regarded as
professional clients as defined under the DFSA rules.
General: Additional information is available upon request. Information has been obtained from sources believed to be reliable but JPMorgan
Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) do not warrant its completeness or accuracy except with respect to any
disclosures relative to JPMSI and/or its affiliates and the analyst’s involvement with the issuer that is the subject of the research. All pricing is as
of the close of market for the securities discussed, unless otherwise stated. Opinions and estimates constitute our judgment as of the date of this
material and are subject to change without notice. Past performance is not indicative of future results. This material is not intended as an offer or
solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual
client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to
particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments
mentioned herein. JPMSI distributes in the U.S. research published by non-U.S. affiliates and accepts responsibility for its contents. Periodic
updates may be provided on companies/industries based on company specific developments or announcements, market conditions or any other
publicly available information. Clients should contact analysts and execute transactions through a J.P. Morgan subsidiary or affiliate in their home
jurisdiction unless governing law permits otherwise.
“Other Disclosures” last revised January 4, 2010.

Copyright 2010 JPMorgan Chase & Co. All rights reserved. This report or any portion hereof may not be reprinted, sold or
redistributed without the written consent of J.P. Morgan.

10
Celine Pannuti, CFA Europe Equity Research
(44-20) 7325-9276 11 February 2010
celine.pannuti@jpmorgan.com

11